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Abstract
Background: Recent evidence suggests that co-clustering of Fas/CD95 death receptor and lipid rafts plays a major role in
death receptor-mediated apoptosis.
Methodology/Principal Findings: By a combination of genetic, biochemical, and ultrastructural approaches, we provide
here compelling evidence for the involvement of lipid raft aggregates containing recruited Fas/CD95 death receptor, Fas-
associated death domain-containing protein (FADD), and procaspase-8 in the induction of apoptosis in human T-cell
leukemia Jurkat cells by the antitumor drug edelfosine, the prototype compound of a promising family of synthetic
antitumor lipids named as synthetic alkyl-lysophospholipid analogues. Co-immunoprecipitation assays revealed that
edelfosine induced the generation of the so-called death-inducing signaling complex (DISC), made up of Fas/CD95, FADD,
and procaspase-8, in lipid rafts. Electron microscopy analyses allowed to visualize the formation of raft clusters and their co-
localization with DISC components Fas/CD95, FADD, and procaspase-8 following edelfosine treatment of Jurkat cells.
Silencing of Fas/CD95 by RNA interference, transfection with a FADD dominant-negative mutant that blocks Fas/CD95
signaling, and specific inhibition of caspase-8 prevented the apoptotic response triggered by edelfosine, hence
demonstrating the functional role of DISC in drug-induced apoptosis. By using radioactive labeled edelfosine and a
fluorescent analogue, we found that edelfosine accumulated in lipid rafts, forming edelfosine-rich membrane raft clusters in
Jurkat leukemic T-cells. Disruption of these membrane raft domains abrogated drug uptake and drug-induced DISC
assembly and apoptosis. Thus, edelfosine uptake into lipid rafts was critical for the onset of both co-aggregation of DISC in
membrane rafts and subsequent apoptotic cell death.
Conclusions/Significance: This work shows the involvement of DISC clusters in lipid raft aggregates as a supramolecular
and physical entity responsible for the induction of apoptosis in leukemic cells by the antitumor drug edelfosine. Our data
set a novel framework and paradigm in leukemia therapy, as well as in death receptor-mediated apoptosis.
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Introduction
In the last few years, a growing amount of evidence suggests that
apoptosis induced by Fas/CD95 death receptor is mediated by the
formation of Fas/CD95 aggregates in lipid rafts [1–7]. Clustering
of death receptor Fas/CD95 can be achieved not only by
interaction with its natural ligand FasL/CD95L, but through
non-physiological agents independently of its ligand [1,4,8],
providing a new framework for novel therapeutic interventions
[6]. This ligand-independent activation of Fas/CD95 has a great
potential therapeutic utility as it avoids the toxic side effects
derived from the use of FasL/CD95L and agonistic anti-Fas/
CD95 antibodies in vivo, that lead to a fatal hepatic damage with
symptoms similar to fulminant hepatitis [9,10].
Edelfosine (ET-18-OCH3,1 - O-octadecyl-2-O-methyl-rac-
glycero-3-phosphocholine) is the prototypic compound of a
promising family of synthetic antitumor lipids, collectively named
as synthetic alkyl-lysophospholipid analogues [11], which induce
selective apoptosis in tumor cells while sparing normal cells [12].
Edelfosine acts through activation of the apoptotic machinery in
cancer cells, involving death receptors, caspase activation, JNK/c-
Jun signaling and mitochondria [1,4,13–18], and therefore this
apoptosis-targeted drug could be appropriate for diseases where
apoptosis is altered. Edelfosine was the first antitumor drug
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independent activation of Fas/CD95 by its recruitment in lipid
rafts [1], linking for the first time membrane rafts and Fas/CD95-
mediated apoptosis in cancer chemotherapy. The proapoptotic
capacity of edelfosine was higher against cancer cells derived from
blood malignancies than from solid tumors [19].
Stimulation of Fas/CD95 results in receptor aggregation and
recruitment of the adapter molecule Fas-associated death domain-
containing protein (FADD), through interaction between its own
death domain and the clustered receptor death domains. FADD,
in turn, contains a death effector domain that binds to an
analogous domain repeated in tandem within the zymogen form of
procaspase-8, forming the so-called death-inducing signaling
complex (DISC), made up of Fas/CD95, FADD and procas-
pase-8 [20], which drives cells to apoptosis.
Despite previous findings that suggest a role of Fas/CD95 and
lipid rafts in cancer chemotherapy [1,4–7,21], compelling
evidence and visualization of the involvement of DISC-enriched
raft clusters in cancer treatment is still lacking. Here, by using
genetic, biochemical and ultrastructural approaches, we demon-
strate the formation and role of DISC co-clustering in membrane
rafts during edelfosine-induced apoptosis, setting up a new
framework in leukemia therapy.
Results
Biochemical and ultrastructural evidence for the
formation of DISC–enriched raft clusters in Jurkat cells
treated with edelfosine
We have previously reported that edelfosine induced co-
aggregates of rafts and Fas/CD95 in leukemia Jurkat T-cells and
multiple myeloma cells [1,4,7]. The proapoptotic complex DISC
was generated upon multiple myeloma cell treatment with
edelfosine [7]. Here, we extend these results by finding that Fas/
CD95 as well as downstream signaling molecules FADD and
procaspase-8 were translocated into membrane rafts (Figure 1A),
forming the proapoptotic complex DISC in lipid rafts (Figure 1B),
upon edelfosine treatment of Jurkat leukemic T-cells. In contrast,
co-immunoprecipitation assays conducted in untreated Jurkat cells
rendered no DISC formation (data not shown). Lipid rafts were
identified using cholera toxin (CTx) B subunit conjugated to
horseradish peroxidase that binds to the oligosaccharide portion of
ganglioside GM1 [22,23], mainly found in lipid rafts [24].
To visualize and further define the co-clustering of DISC and
membrane rafts following edelfosine incubation, we used electron
microscopy. This technique preserved the ultrastructural integrity
of the membrane and allowed immunolabeling for DISC
constituents. In untreated Jurkat cells, we only detected very
disperse and weak staining of rafts and Fas/CD95 at the plasma
membrane without co-localization between both labels (data not
shown). However, edelfosine treatment of Jurkat cells induced
clusters of lipid rafts, identified through CTx B subunit binding, at
the cell surface (Figure 2A). Fas/CD95 was located embedded in
plasma membrane rafts upon edelfosine treatment (Figure 2B),
thus indicating the translocation and recruitment of Fas/CD95
death receptor into membrane rafts at the cell surface. Following
drug treatment and using immunogold electron microscopy,
FADD was immunolocalized together with Fas/CD95 and rafts,
facing the cytoplasmic side of the membrane (Figure 2C).
Furthermore, procaspase-8 was also localized in the same region
in edelfosine-treated cells, forming DISC aggregates in discrete
zones of the plasma membrane enriched in lipid rafts after drug-
treated Jurkat cells were labeled with specific antibodies to each
DISC component and with CTx B subunit to identify membrane
rafts (Figure 2D). The presence of multiple gold particles, labeling
rafts (Figure 2A–2D) and DISC components (Figure 2B–2D),
suggests a high local molecule concentration of DISC constituents
in raft platforms, in keeping with the formation of DISC-rich raft
clusters. Our data visualize for the first time the formation of co-
clusters of DISC in lipid rafts in cancer chemotherapy, and further
demonstrate the role of membrane rafts as scaffolds to concentrate
Fas/CD95 and downstream signaling molecules in small and
specialized areas of the cell surface following edelfosine treatment.
Functional role of Fas/CD95, FADD, and caspase-8 in
drug-induced apoptosis in Jurkat cells
To investigate the role of DISC in edelfosine-induced apoptosis,
we inhibited the endogenous expression of Fas/CD95 in Jurkat
cells by RNA interference using short hairpin RNA (shRNA). This
Fas/CD95 silencing resulted in a significant loss of Fas/CD95
protein expression (Figure 3A) and inhibition of edelfosine-induced
apoptosis (Figure 3B). Transfection of Jurkat cells with one of the
four target sequences used for Fas/CD95 silencing (target
sequence 1 in the Materials and Methods section) led to clones
with about 65% Fas/CD95 silencing (Figure 3A). This downreg-
ulation of Fas/CD95 protein expression was further assessed by
Western blotting and by mean fluorescence intensity measure-
ments in flow cytometry analysis (data not shown). This partial
Fas/CD95 silencing led to about 70% inhibition in edelfosine-
induced apoptosis after 48-h drug incubation (Figure 3B).
Apoptosis rates were determined by measuring the percentage of
cells at the sub-G1 region in cell cycle analysis (Figure 3B). Analysis
of the distinct cell cycle phases showed that Fas/CD95 silencing
promoted a slight G2/M arrest following edelfosine treatment
(Figure 3B). Cell transfection with a control vector containing a
scrambled sequence did not affect either Fas/CD95 expression
(Figure 3A) or drug-induced apoptosis (Figure 3B), and no changes
were detected in the distinct cell cycle phases before the triggering
of apoptosis (Figure 3B). Likewise, additional Fas/CD95 shRNA
vectors that did not silence Fas/CD95 expression were without
Figure 1. DISC formation in lipid rafts following Jurkat cell
incubation with edelfosine. (A) Untreated control Jurkat cells
(Control) and Jurkat cells treated with 10 mM edelfosine (EDLF) for
9 h were analyzed for lipid raft isolation on a discontinuous sucrose
density gradient. Raft and non-raft fractions were analyzed by Western
blotting for the indicated proteins using specific antibodies. The
migration positions of the 55-kDa procaspase-8 as well as of the
cleavage product p18 are denoted. Location of GM1-containing lipid
rafts was determined using CTx B subunit conjugated to horseradish
peroxidase. (B) Fas/CD95 was immunoprecipitated from the raft fraction
of edelfosine-treated Jurkat cells. Immunoprecipitates were subjected
to SDS-PAGE and immunoblotted with Fas/CD95, FADD- and procas-
pase-8 specific antibodies, respectively. Raft fraction was also immu-
noprecipitated with P3X63 (X63) myeloma supernatant as a negative
control. Experiments shown are representative of three performed.
doi:10.1371/journal.pone.0005044.g001
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shown). Cells transfected with control vector behaved similarly to
intact nontransfected Jurkat cells, regarding either Fas/CD95
protein expression or drug-induced apoptosis (data not shown).
Using stable transfection in Jurkat cells with a dominant-
negative form of the FADD adapter protein (FADD-DN), which
lacks the death effector domain and prevents death receptor
signaling [25], we found that blockade of Fas/CD95 downstream
signaling abrogated edelfosine-induced apoptosis (about 80%
inhibition after 48-h drug incubation) (Figure 4A and 4B).
Conversely, transfection with a control pcDNA3 empty vector
did not affect edelfosine-induced apoptosis (Figure 4A). Cells
transfected with pcDNA3 control vector behaved similarly to
intact nontransfected Jurkat cells regarding drug-induced apopto-
sis (data not shown).
Furthermore, the cell-permeable specific caspase-8 inhibitor z-
IETD-fmk (N-benzyloxycarbonyl-Ile-Glu-Thr-Asp-fluoromethyl
ketone) strongly inhibited (about 70% inhibition) edelfosine-
induced apoptosis (Figure 5).
The above results show that silencing or inhibition of the three
major components of DISC prevents the apoptotic response
induced by edelfosine in Jurkat cells as assessed by cell cycle
Figure 2. Ultrastructural localization of DISC embedded in lipid rafts during edelfosine treatment of leukemic cells. (A–D) Electron
microscopy images of Jurkat cells treated with 10 mM edelfosine (EDLF) for 9 h. Sections of edelfosine-treated cells were labeled with the raft marker
GM1 using CTx B subunit (6-nm gold) alone (A), or in combination with anti-Fas/CD95 antibody (10-nm gold) (B). Drug-treated cells were also labeled
with the raft marker GM1 using CTx B subunit (6-nm gold) (asterisk), anti-Fas/CD95 antibody (10-nm) (closed arrowhead), anti-FADD antibody (15-nm)
(arrow) (C), and anti-procaspase-8 antibody (20-nm) (open arrowhead) (D). Lipid rafts are labeled on the external face of the membrane, whereas DISC
components are located in the internal face of raft-enriched membrane domains. Bar, 400 nm.
doi:10.1371/journal.pone.0005044.g002
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analyzed apoptosis by the terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) technique [26] as an
in situ method for detecting the 39-OH ends of DNA exposed
during the internucleosomal cleavage that occurs during apoptosis
(Figure 6). Labeling the 39-OH ends, generated by DNA
fragmentation, through incorporation of fluoresecin-12-dUTP
allowed visualization of apoptotic cells. In addition, cells were
permeabilized and stained with propidium iodide to visualized all
nuclei from both non-apoptotic and apoptotic cells in red, while
TUNEL-positive cells were stained in green. Silencing of Fas/
CD95 by RNA interference (Figure 6A and 6B), constitutive
expression of FADD-DN (Figure 6A and 6C), and inhibition of
caspase-8 with z-IETD-fmk (Figure 6A and 6D) strongly inhibited
edelfosine-induced apoptosis, as assessed by TUNEL analysis. The
apoptotic rate, measured by this TUNEL technique, of untreated
cells or Jurkat cells treated only with the caspase-8 inhibitor z-
IETD-fmk, run in parallel, was less than 3% in all cases (data not
shown). Similar apoptosis rates were obtained using cell cycle
(hypodiploidy) and TUNEL analyses (Figures 3–6).
Taken together, we found that targeting each of the three
components of DISC precludes the induction of apoptosis by the
alkyl-lysophospholipid analogue edelfosine. These results strongly
indicate that DISC regulates edelfosine-induced apoptosis in
leukemic cells.
Accumulation of edelfosine in lipid rafts and raft
requirement for drug uptake and apoptosis
Edelfosine itself accumulated in lipid rafts, as assessed by the
presence of [
3H]edelfosine in isolated rafts from Jurkat cells
(Figure 7A). Furthermore, the fluorescent analogue PTE-edelfo-
sine (all-[E]-1-O-[159-phenylpentadeca-89,109,129,149-tetraenyl]-2-
O-methyl-rac-glycero-3-phosphocholine), which behaves similarly to
Figure 3. Edelfosine-induced apoptosis in Jurkat cells is
mediated by Fas/CD95. (A) Cells were transfected with Fas/CD95
shRNA (target sequence 1, Materials and Methods) (Fas shRNA) or
neomycin-resistant scrambled sequence control vector (Vector), and the
percentage of Fas/CD95 positive cells was assessed by flow cytometry
using P3X63 (X63) myeloma supernatant as a negative control. (B)
Jurkat cells transfected with neomycin-resistant scrambled sequence
control vector (Vector) or Fas/CD95 shRNA (target sequence 1, Materials
and Methods) (Fas shRNA) were treated with 10 mM edelfosine-induced
apoptosis for the indicated incubation times and the proportion of cells
in each phase of the cell cycle was quantitated by fluorescence flow
cytometry. Cells in the sub-G1 region represent apoptotic cells.
Untreated control cells were run in parallel. Data are shown as
means6SE of four independent experiments.
doi:10.1371/journal.pone.0005044.g003
Figure 4. Edelfosine-induced apoptosis in Jurkat cells is
mediated by FADD. Cells, stably transfected with control pcDNA3
empty vector (Vector) (A) or FADD-DN (B), were treated with 10 mM
edelfosine for the indicated incubation times, and the proportion of
cells in each phase of the cell cycle was quantified by flow cytometry.
Cells in the sub-G1 region represent apoptotic cells. Untreated cells
were run in parallel. Data are shown as means6SE of four independent
experiments.
doi:10.1371/journal.pone.0005044.g004
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rich lipid raft clusters in leukemic T-cells (Figure 7B). A higher
magnification of the images showed a good co-localization between
the green staining of the raft marker fluorescein isothiocyanate-
labeled CTx B subunit and PTE-edelfosine (Figure 7C). Figures 7B
and7Calsoshowtheclusteringandcappingoflipidraftsinducedby
edelfosine treatment. Rafts as well as PTE-edelfosine were mainly
concentrated in dense patches in one or two poles of the Jurkat cell
(Figure 7B and 7C).
Preincubation with parental edelfosine prevented labeling of
cells with the fluorescent analogue (data not shown). Disruption of
lipid rafts with methyl-b-cyclodextrin (MCD), which interferes
with protein association to rafts by cholesterol depletion [1,27],
inhibited drug uptake (Figure 7D), DISC formation (data not
shown) and apoptosis (Figure 7E). No patchy localization of the
edelfosine fluorescent analogue was observed at the cell surface of
MCD-treated cells (data not shown). These results square with our
previous observation that lipid raft disruption abrogated edelfo-
sine-induced formation of Fas/CD95 clusters [1,4]. Drug uptake
was monitored after exhaustive washing of cells with bovine serum
albumin (BSA), for which edelfosine shows a high binding capacity
[28,29]. Thus, incorporated edelfosine seems to be accumulated in
the inner leaflet of the plasma membrane in order to be
inaccessible to extracellularly added albumin.
Discussion
Our data demonstrate that the synthetic alkyl-lysophospholipid
analogue edelfosine targets lipid rafts in Jurkat leukemic T-cells,
and that intact rafts are crucial for both drug uptake and drug-
induced apoptosis, serving as scaffolds for DISC recruitment. The
present results extend and complement our earlier findings on the
role of CD95 signaling and lipid rafts in the triggering of apoptosis,
and lead to the scheme depicted in Figure 8, as a novel framework
in cancer therapy. Here we have shown, by using different
experimental approaches, the formation and role of co-clusters of
DISC and membrane rafts in the triggering of apoptosis during
edelfosine antileukemic action. Crucial to this process is the
accumulation of edelfosine in lipid rafts, which is ensued by the
reorganization of membrane raft protein and lipid composition
[4,7,30] that leads to the recruitment of DISC in rafts. The
aggregation of DISC in membrane rafts would favor caspase-8
activation, and hence apoptosis, as the basal activity of procaspase-
8 is put in function by proximity [31]. Thus, the concentration of
DISC in a rather small region of the plasma membrane facilitates
caspase-8 activation that eventually leads to apoptosis. Our present
findings indicate that membrane rafts serve, in addition to
generating high local concentrations of Fas/CD95, as platforms
for coupling adapter (FADD) and effector (caspase-8) proteins
required for Fas/CD95 signaling. This is of particular importance
in Fas/CD95-mediated signal transduction as the initial signaling
events depend on protein-protein interactions [1,4,8]. We have
previously shown that edelfosine is taken up preferentially by
tumor cells [12,16], and trigger a Fas/CD95-mediated apoptotic
response from within the cell independently of the ligand FasL/
CD95L [4]. Taken together, these data suggest that formation of
DISC-raft clusters can be pharmacologically modulated with
promising therapeutic prospects in cancer therapy.
Recent evidence shows that the novel antitumor drugs aplidin
and perifosine also induce translocation of Fas/CD95 and
downstream signaling molecules into lipid rafts in leukemia cells
[5,7,32]. In addition, cis-platin and resveratrol have been reported
to elicit co-clustering of Fas/CD95 and rafts in solid tumors
[21,33]. Thus, there is an increasing evidence suggesting that Fas/
CD95 translocation into lipid rafts represents a mechanism of
action for anticancer drugs. The data reported here demonstrate
the formation of DISC-enriched raft aggregates as a linchpin from
which apoptosis is triggered. On these grounds, we postulate that
co-aggregation of lipid rafts and Fas/CD95-DISC is a new
framework and paradigm in anticancer therapy. Interestingly,
edelfosine and aplidin, two anticancer drugs that promote
recruitment of Fas/CD95 in lipid rafts, accumulate in death
receptor-rich rafts [1,4,5]. Likewise, perifosine also binds to lipid
rafts [34] and promotes Fas/CD95 translocation in rafts [7].
Taken together, these results establish membrane rafts as an
attractive target in cancer therapy, and edelfosine antitumor action
as a paradigm of this novel raft/death receptor-mediated
mechanism of action. This translocation of Fas/CD95-DISC into
raft clusters, leading to Fas/CD95-mediated apoptosis indepen-
dently of FasL/CD95L, provides a new molecular insight into
leukemia chemotherapy and in the triggering of death receptor-
mediated apoptosis.
Materials and Methods
Cell culture
The human acute T-cell leukemia Jurkat cell line was grown in
RPMI-1640 culture medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin at 37uCi n
humidified 95% air and 5% CO2. The Jurkat-FADD-DN cell line,
provided by M.L. Schmitz (Justus-Liebig-University, Giessen,
Germany), is a Jurkat-derived clone stably transfected with a
pcDNA3 expression vector encoding a dominant-negative form of
the FADD protein [25]. This Jurkat-FADD-DN cell line
constitutively expresses FADD-DN, thus blocking Fas/CD95
downstream signaling [25], and was maintained in complete
Figure 5. Edelfosine-induced apoptosis in Jurkat cells is
mediated by caspase-8. Cells were preincubated without or with
50 mM of z-IETD-fmk for 1 h, and then incubated in the absence or
presence of 10 mM edelfosine (EDLF) for 24 h, and analyzed by flow
cytometry to evaluate apoptosis. Untreated control cells were run in
parallel. Data are shown as means6SE of three independent
experiments.
doi:10.1371/journal.pone.0005044.g005
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transfected with control pcDNA3 empty vector using Lipofecta-
mine 2000 (Invitrogen/Life Technologies, Carlsbad, CA) accord-
ing to the manufacturer’s instructions.
Apoptosis assay by flow cytometry
Quantitation of apoptotic cells, following treatment with
edelfosine (INKEYSA, Barcelona, Spain; APOINTECH, Sala-
manca, Spain), was calculated by flow cytometry as the percentage
of cells in the sub-G1 region (hypodiploidy) in cell cycle analysis as
previously described [17].
TUNEL assay
Apoptosis was also analyzed in situ by the TUNEL technique
using the Fluorescein Apoptosis Detection System (Promega,
Madison, WI), according to the manufacturer’s instructions. Cells
were fixed on microscope slides, permeabilized with 0.2% Triton
X-100, stained for fragmented DNA using the above kit, and then
propidium iodide was added for 15 min to stain both apoptotic
and non-apoptotic cells as previously described [16,35]. Thus,
propidium iodide stains apoptotic and non-apoptotic cells in red,
whereas fluoresecin-12-dUTP is incorporated at the 39-OH ends
of fragmented DNA [26], resulting in localized green fluorescence
within the nucleus of apoptotic cells. Samples were analyzed with a
Zeiss LSM 510 laser scan confocal microscope.
Edelfosine uptake
Drug uptake was measured as described previously [12] after
incubating cells (10
6) with 10 nmol [
3H]edelfosine (10 mM) for 1 h
in RPMI-1640/10% FBS, and subsequent exhaustive washing (six
times) with PBS+2% BSA. [
3H]edelfosine (specific activity, 42 Ci/
mmol) was synthesized by tritiation of the 9-octadecenyl derivative
(Amersham Buchler, Braunschweig, Germany).
Edelfosine localization by fluorescence microscopy
Jurkat cells were treated for 9 h with 10 mM fluorescent analog
PTE-edelfosine, provided by A.U. Acun ˜a and F. Amat-Guerri
(Consejo Superior de Investigaciones Cientı ´ficas, Madrid, Spain),
which behaves similarly to the parental compound [4,19], and
then incubated with the raft marker fluorescein isothiocyanate-
CTx B subunit to label lipid rafts as described previously [1,4]. Co-
localization of the distinct fluorochromes was analyzed, by
excitation of the corresponding fluorochromes in the same section
of samples, using a fluorescence microscope (Axioplan 2; Carl
Zeiss MicroImaging, Inc.) and a digital camera (ORCA-ER-1394;
Hamamatsu).
Figure 6. Involvement of DISC constituents in edelfosine-induced apoptosis as assessed by TUNEL assay. (A) Jurkat cells transfected
with neomycin-resistant scrambled sequence control vector (Vector) or Fas/CD95 shRNA (target sequence 1, Materials and Methods) (Fas shRNA)
(upper panel), and with control pcDNA3 empty vector (Vector) or FADD-DN (middle panel), were treated with 10 mM edelfosine (EDLF)-induced
apoptosis for 20 h, and analyzed by confocal microscopy for differential interference contrast (DIC), propidium iodide (PI) staining and TUNEL assay.
Merging of PI and TUNEL panels (Merge) shows the apoptotic nuclei in yellow. Jurkat cells were also untreated (Control), treated with 10 mM
edelfosine for 20 h (EDLF), or preincubated with 50 mM of z-IETD-fmk for 1 h followed by incubation in the presence of 10 mM edelfosine for 20 h (z-
IETD-fmk+EDLF), and then analyzed by confocal microscopy for DIC, PI staining and TUNEL assay as above (lower panel). Data shown are
representative of four independent experiments. Bar, 10 mm. (B–D) Histograms indicate the percentage of TUNEL-positive cells, as an estimate of cells
undergoing apoptosis, following the experimental conditions shown in A (upper, middle and lower panels). For each experiment at least 120 cells
were analyzed. Data are shown as means6SE of four independent experiments.
doi:10.1371/journal.pone.0005044.g006
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Jurkat cells in culture medium were fixed 1:1 (v/v) with 4%
paraformaldehyde+0.4% glutaraldehyde pH 7.4 in 0.2 M PHEM
buffer (60 mM PIPES, 25 mM HEPES, 2 mM MgCl2,1 0m M
EGTA) for 30 min at room temperature. Cells were washed in
PHEM and treated with 40 mM glycine. Lipid rafts were detected
by incubation for 1 h at room temperature with cholera toxin
(CTx) B subunit conjugated to biotin (Invitrogen, San Diego, CA)
diluted 1:10 in blocking solution (PHEM-2% BSA). Cells were
washed with PBS and incubated for 1 h at room temperature with
6-nm gold particles conjugated to streptavidin (Electron Micros-
copy Sciences, Hatfield, PA), diluted 1:40 in PBS. Cells were then
fixed overnight in 2% glutaraldehyde in PHEM buffer. Samples
were treated for electron microscopy by postfixing the cells for 1 h
in 1% osmium tetroxide in phosphate buffer pH 7.4 containing
1% CaCl2. Cells were then embedded in Durcupan resin (Fluka/
Sigma Aldrich, Buchs, Switzerland). Ultrathin sections were
mounted on formvar-coated nickel grids and stained with 2%
uranyl acetate for 20 min and lead citrate for 2 min. Grids were
examined on a Zeiss EM 900 at 80 kV accelerating voltage. Cells
without lipid raft labeling were used as negative controls, showing
no staining of the samples.
Cells with labeled lipid rafts were fixed in 2% paraformaldehyde
plus 0.5% glutaraldehide in 0.1 M PHEM buffer overnight and
embedded in London Resin White (London Resin Company,
Berkshire, UK). Ultrathin sections were mounted on formvar-
coated nickel grids. Visualization of lipid rafts was processed as
above using 6-nm gold particles conjugated to streptavidin. For
immunolabeling, grids were floated at room temperature on drops
containing 40 mM glycine in TBST (50 mM Tris-HCl, pH 8.0,
150 mM NaCl, 0.05% Tween) for 30 min to quench unreacted
aldehydes. After blocking with 2% BSA in TBST for 30 min, grids
were incubated for 1 h with goat anti-procaspase-8 antibody (C20)
(Santa Cruz Biotechnology, Santa Cruz, CA) (dilution 1:10 in
blocking solution), and then with anti-goat IgG conjugated with
20-nm gold particles (Electron Microscopy Sciences) (dilution 1:50
in blocking solution). The grids were put successively through PBS,
1% glutaraldehyde in PBS (10 min), PBS, PBS glycine, 2% BSA-
TBST. For double immunolabeling, Fas/CD95 and FADD
proteins were detected following 1 h incubation each with specific
anti-Fas/CD95 (C-20) rabbit antibody (Santa Cruz Biotechnology)
and anti-FADD (clone-1) mouse monoclonal antibody (BD
Transduction Laboratories, Lexington, KY) (dilution 1:10 in
blocking solution). Grids were incubated with a mixture of
Figure 7. Edelfosine accumulation in lipid rafts. (A) Jurkat cells treated with 10 mM[
3H]edelfosine for 9 h were lysed in 1% Triton and
fractionated by centrifugation on a discontinuous sucrose density gradient. An equal volume of each collected fraction was subjected to SDS-PAGE
and counted for radioactivity. The distribution patterns of GM1-containing rafts (upper panel) (fractions 3–5) and [
3H]edelfosine (EDLF) (lower panel)
over the gradient fractions are shown. Data are representative of three separate experiments. (B) Jurkat cells were incubated with 10 mM PTE-
edelfosine (PTE-EDLF, blue fluorescence) for 9 h, and then its co-localization with membrane rafts was examined using fluorescein isothiocyanate-
labeled CTx B subunit (green fluorescence for rafts). Areas of co-localization between membrane rafts and PTE-edelfosine in the merge panel are
cyan. Data are representative of four independent experiments. Bar, 10 mm. (C) Higher magnifications of Jurkat cells treated as in B are shown. Data
are representative of four independent experiments. Bar, 5 mm. (D, E) Jurkat cells were pretreated in the absence or presence of 2.5 mg/ml MCD for
30 min, and then drug uptake was determined after incubation with 10 mM[
3H]edelfosine (EDLF) for 1 h (D), and apoptosis was analyzed by flow
cytometry following incubation with 10 mM edelfosine for 24 h (E). Data are means6SE of three independent determinations.
doi:10.1371/journal.pone.0005044.g007
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IgG linked to 10 nm gold particles, both diluted 1:50 in blocking
solution. In order to reduce background, NaCl concentration was
elevated from 2.5 mM to 2.5 M in 4 changes of 6 min each and
then switched to ultrapure water. Grids were counterstained with
2% uranyl acetate for 20 min in dark and examined in a Zeiss EM
900. Negative controls were prepared by replacing the primary
antibody with a nonrelevant antibody, showing no staining of the
samples.
Transfection of Jurkat cells with Fas/CD95 shRNA
Jurkat cells were successfully transfected with a negative control
neomycin vector containing a scrambled sequence (59-
GGAATCTCATTCGATGCATAC-39) and four pre-designed
Fas/CD95 shRNA vectors (SureSilencing shRNA, SuperArray
Bioscience Corporation, Frederick, MD) containing 4 target
sequences (1: 59-GCTGGAGTCATGACACTAAGT-39;2 :5 9-
GAAGCGTATGACACATTGATT-39;3 :5 9-TTGGAAGGCC-
TGCATCATGAT-39;4 :5 9-AACCAAGGTTCTCATGAATC-
T-39), using Lipofectamine 2000 (Invitrogen), according to the
manufacturer’s instructions. Jurkat cells were plated in 24-well
plates at 3610
4 cells/cm
2. shRNA plasmid (0.5 mg) was mixed
with 50 ml Opti-MEM I reduced-serum medium (Life Technolo-
guies, Gaithersburg, MD) for 10 min at room temperature.
Lipofectamine 2000 (1 ml) was diluted in 50 ml Opti-MEM
medium and mixed gently with the shRNA solution. After a 20-
min incubation at room temperature, mixture was added to the
cells in a final volume of 0.5 ml/well. Transfected cells were
cultured at 37uC in humidified 95% air and 5% CO2 for 48 h, and
then neomycin-resistant clones were selected using G418 (1 mg/
ml). Silencing of Fas/CD95 expression was confirmed by flow
cytometry and Western blotting. Only one (target sequence 1) of
Figure 8. Schematic model for the involvement of DISC and lipid rafts in edelfosine-induced apoptosis in Jurkat cells. This diagram
portrays a currently plausible mechanism for the role of DISC recruitment in membrane rafts in drug-induced apoptosis based on the results reported
in this work. Initially, Fas/CD95 death receptor is not located at the membrane raft regions of plasma membrane. Incubation of Jurkat cells with
edelfosine (EDLF) leads to its accumulation in membrane rafts, inducing raft clustering and recruitment of Fas/CD95 into lipid rafts. This translocation
and concentration of Fas/CD95 in rafts brings together FADD and procaspase-8, forming the DISC, through protein-protein homotypic interactions
between their respective death domains (DD) and death effector domains (DED). Thus, lipid raft clusters act as scaffolds where DISC is concentrated,
hence achieving caspase-8 activation and eventually apoptosis. These DISC-raft co-clusters would behave as a supramolecular and physical entity
crucial for the death receptor-mediated regulation of apoptosis.
doi:10.1371/journal.pone.0005044.g008
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CD95 expression (about 65% inhibition).
Immunofluorescence flow cytometry
Cell surface expression of Fas/CD95 death receptor was
analyzed by flow cytometry in 4610
5 cells as described previously
[16] in a Becton Dickinson FACSCalibur
TM flow cytometer using
an anti-Fas/CD95 SM1/1 monoclonal antibody (Bender Med-
Systems, Vienna, Austria). P3X63 myeloma culture supernatant,
provided by F. Sa ´nchez-Madrid (Hospital de La Princesa, Madrid,
Spain), was used as a negative control.
Lipid raft isolation
Lipid rafts were isolated from 8610
7 cells by nonionic detergent
lysis and centrifugation on discontinuous sucrose gradients as
described [1,4]. Twelve fractions (1-ml) were collected from the
top of the gradient and 20 ml of each fraction were subjected to
SDS-PAGE, immunoblotting and enhanced chemiluminescence
detection. Location of GM1-containing lipid rafts was determined
using CTx B subunit conjugated to horseradish peroxidase
(Sigma). Pools of fractions 3–5 (enriched in lipid rafts) and
fractions 10–12 (largely deficient in lipid rafts) from these sucrose
gradients led to the raft and non-raft fractions, respectively, which
were subsequently subjected to Western blotting. Proteins were
identified using specific antibodies: anti-48-kD Fas/CD95 (C-20)
rabbit polyclonal antibody (Santa Cruz Biotechnology), anti-29-
kD FADD (clone-1) (BD Transduction Laboratories) monoclonal
antibody, and anti-55-kDa procaspase-8 (Ab-3) monoclonal
antibody (Oncogene Research Products, Cambridge, MA).
Co-immunoprecipitation assays
Fractions 3–5 from the lipid raft isolation sucrose gradient were
mixed and incubated with lysis buffer (20 mM Tris-HCl, pH 7.5,
100 mM KCl, 0.9% Triton X-100, 10% glycerol, 2 mM Na3VO4,
2 mM PMSF). Lysates were precleared with protein A-Sepharose,
and immunoprecipitated with anti-Fas/CD95 (C-20) rabbit
polyclonal antibody precoupled to protein A-Sepharose as
previously described [7,36]. Samples were subjected to SDS-
PAGE and immunoblotted with specific antibodies against FADD
and procaspase-8. Membrane raft pools were also immunopre-
cipitated with P3X63 myeloma supernatant as a negative control
showing no signal.
Cholesterol depletion
For cholesterol depletion, 2.5610
5 cells/ml were pretreated
with 2.5 mg/ml MCD for 30 min at 37uC in serum-free medium.
Cells were then washed three times with PBS and resuspended in
complete culture medium before edelfosine addition.
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